Keeping you up to date on recent developments in oncology, including: Imaging studies offer clarity on impact of combo therapy in metastatic breast cancer; Antidiarrheal drug fights AML; Peering past gastrointestinal mucosa to find tumors; Nanosac to the rescue for solid tumor therapy.
A team led by researchers at Johns Hopkins University School of Medicine has developed bispecific antibodies that were able to target tumors driven by mutations in the tumor suppressor TP53 and the oncogene RAS, as well as subsets of T cells in T-cell malignancies.
Keeping you up to date on recent developments in diagnostics, including: Atherosclerosis precedes clonal hematopoiesis; AI-driven tool to assess kidney function; Deep learning-powered classification of lung cancer types.
Scientists, despite their best efforts, have not been able to identify a way to inhibit the oncoprotein Myc. Uropathogenic Escherichia coli, though, has apparently figured it out.
RNA has “huge potential” as a therapeutic modality and is beginning to deliver on that potential. But “manufacturing RNA has issues in production, delivery and performance,” Thomas Barnes told BioWorld. Barnes is the CEO of startup Orna Therapeutics LLC, which has the goal of addressing those issues with oRNA, an engineered form of circular RNA.
Keeping you up to date on recent developments in oncology, including: MR touted as potential screening modality for prostate cancer; Classifying variants of unknown significance; Tumor neoantigens can inhibit immune response; MEK perhaps a useful target in some bladder cancers.
